AK Global Asset Management LLC Takes $9.06 Million Position in AbbVie Inc. $ABBV

AK Global Asset Management LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 39,645 shares of the company’s stock, valued at approximately $9,058,000. AbbVie comprises about 7.9% of AK Global Asset Management LLC’s portfolio, making the stock its 3rd biggest holding.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Evolution Wealth Management Inc. bought a new position in AbbVie during the 2nd quarter worth approximately $26,000. Chelsea Counsel Co. bought a new position in AbbVie during the 3rd quarter worth approximately $26,000. Westend Capital Management LLC bought a new position in AbbVie during the 4th quarter worth approximately $29,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie during the 3rd quarter worth approximately $31,000. Finally, Caitlin John LLC bought a new position in AbbVie during the 3rd quarter worth approximately $33,000. Institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on ABBV shares. Morgan Stanley lifted their price objective on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Royal Bank Of Canada started coverage on shares of AbbVie in a research note on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective on the stock. William Blair reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Barclays began coverage on shares of AbbVie in a research note on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective on the stock. Finally, Evercore cut their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is owned by company insiders.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: JPMorgan calls the recent pullback a buying opportunity and reiterates confidence with a $260 price target, arguing valuation and long‑term cash flow from immunology and aesthetics create upside for ABBV. AbbVie Gets JPMorgan Buying Opportunity Call
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) opened a new AMI training center in Austin, strengthening commercial support and physician training for aesthetics products — a gradual, supportive tailwind for the aesthetics portfolio. Allergan Aesthetics Third AMI Center Opens
• Neutral Sentiment: AbbVie updated an ongoing real‑world Parkinson’s observational study in Belgium — progress on neurology evidence can support longer‑term pipeline value, but this is an informational update without immediate commercial impact. AbbVie’s Real‑World Parkinson’s Study
• Neutral Sentiment: Analyst coverage is mixed but constructive: the stock retains an average “Moderate Buy” rating, and several articles revisit valuation, dividend yield and upcoming Q1 earnings (April 29) as key decision points for investors. These views temper panic but don’t change fundamentals immediately. Analyst Average Rating
• Negative Sentiment: AbbVie agreed to list Humira on the TrumpRx discount program at an ~86% discount under a White House pricing pact — this is a major pricing concession for a legacy blockbuster and increases near‑term revenue risk and valuation uncertainty for the post‑exclusivity Humira franchise. AbbVie Puts Humira on TrumpRx
• Negative Sentiment: AbbVie lowered its Q1 and FY‑2026 outlook after taking a $744M R&D charge — the guide cut and one‑time charge weigh on near‑term EPS trajectory and help explain recent share weakness. AbbVie Lowers Q1 and FY‑2026 Outlook
• Negative Sentiment: Market commentary and headlines note ABBV underperformed peers and shares have pulled back ~12% over the past month — amplifying investor sensitivity to guidance, Humira pricing moves, and upcoming earnings. AbbVie Stock Drops Despite Market Gains

AbbVie Stock Down 0.2%

NYSE ABBV opened at $206.21 on Wednesday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company has a market capitalization of $364.61 billion, a PE ratio of 87.38, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. The firm’s 50 day moving average is $220.95 and its 200-day moving average is $224.28.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period last year, the company earned $2.16 earnings per share. The firm’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. AbbVie’s dividend payout ratio (DPR) is 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.